IPP Bureau
Advent to sell generic drugmaker Zentiva to GTCR
By IPP Bureau - September 16, 2025
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
HCHB and element5 form strategic alliance to accelerate the agentic AI movement in post-acute care
By IPP Bureau - September 16, 2025
Element5’s Agentic AI platform will be integrated with the HCHB EHR
Kerala to host Ayush Mission workshop on “IT solutions in the Ayush sector”
By IPP Bureau - September 16, 2025
The discussions are expected to pave the way for the creation of a consolidated national knowledge-sharing platform on IT-enabled Ayush services,
Philips and Masimo partner to advance access to patient monitoring technologies
By IPP Bureau - September 16, 2025
Philips and Masimo will also collaborate on the development and co-promotion of next-generation monitoring solutions
Mycenax and Spera forge alliance to streamline ADC drug substance
By IPP Bureau - September 16, 2025
FDA launches crackdown on deceptive drug advertising
By IPP Bureau - September 16, 2025
The FDA is beginning rulemaking to close the “adequate provision” loophole
Novo Nordisk’s amylin therapy cagrilintide shows significant weight loss in phase 3 trial
By IPP Bureau - September 16, 2025
Cagrilintide represents a novel approach to obesity management
Galimedix completes phase 1 study with oral small molecule GAL-101
By IPP Bureau - September 16, 2025
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Biocartis receives FDA approval for Idylla CDx MSI test
By IPP Bureau - September 16, 2025
First fully automated, cartridge-based companion diagnostic test for colorectal cancer patients approved in the United States
Dr. Reddy’s launches novel molecule ‘Tegoprazan’ in India
By IPP Bureau - September 16, 2025
Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB
Cadila launches nutritional replenisher ‘Nu Nutridac’ capsule
By IPP Bureau - September 16, 2025
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
AstraZeneca’s Phase III FLAURA2 trial shows positive result
By IPP Bureau - September 15, 2025
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China
By IPP Bureau - September 15, 2025
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Yatharth Hospitals acquires Shantived Hospital in Agra for Rs. 260 Cr
By IPP Bureau - September 14, 2025
Shantived Hospital generated revenue of around Rs 50 crore in FY2025
